arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2013-19-3-212-220arthyper-139Research ArticleОРИГИНАЛЬНАЯ СТАТЬЯORIGINAL ARTICLEВЛИЯНИЕ АНТИ В-КЛЕТОЧНОЙ ТЕРАПИИ НА ЖЕСТКОСТЬ СОСУДИСТОЙ СТЕНКИ У БОЛЬНЫХ СИСТЕМНОЙ СКЛЕРОДЕРМИЕЙTHE IMPACT OF ANTI B-CELL THERAPY ON ARTERIAL STIFFNESS IN SYSTEMIC SCLERODERMAМаслянскийА. Л.MaslyanskiyA. L.

Кандидат медицинских наук, старший научный сотрудник научно-исследовательской лаборатории ревматологии ФЦСКЭ им. В.А. Алмазова.

Контактная информация: ФГБУ ≪Федеральный Центр сердца, крови и эндокринологии им. В.А. Алмазова≫ Министерства здравоохранения Российской Федерации, ул. Аккуратова, д. 2, Санкт-Петербург, Россия, 197341. E-mail: esc_4@mail.ru (Маслянский Алексей Леонидович).

Corresponding author: Almazov Federal Heart, Blood and Endocrinology Centre, 2 Akkuratov st., St Petersburg, Russia, 197341. E-mail: esc_4@mail.ru (Alexei L. Maslyanskiy, Senior Researcher in Scientifi c Laboratory of Rheumatology at Almazov Federal Heart, Blood and Endocrinology Centre).

esc_4@mail.ruКолесоваЕ. П.KolesovаE. P.

Научный сотрудник научно-исследовательской лаборатории эпидемиологии артериальной гипертензии ФЦСКЭ им. В.А. Алмазова

esc_4@mail.ruПенинИ. Н.PeninI. N.

Заочный Аспирант ФЦСКЭ им. В.А. Алмазова

esc_4@mail.ruЧешуинаМ. Д.CheshuinaM. D.

Заочный Аспирант ФЦСКЭ им. В.А. Алмазова

esc_4@mail.ruЛапинС. В.LapinS. V.

Кандидат медицинских наук, заведующий лабораторией диагностики аутоиммунных заболеваний ГБОУ ВПО «Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России

esc_4@mail.ruКонрадиА. О.KonradiA. O.

Доктор  медицинских наук, профессор, руководитель научно-исследовательского отдела артериальной гипертензии, заместитель директора по научной работе ФЦСКЭ им. В.А. Алмазова

esc_4@mail.ruФедеральный Центр сердца, крови и эндокринологии им. В.А. Алмазова, Санкт-ПетербургРоссияAlmazov Federal Heart, Blood and Endocrinology Centre, St PetersburgRussian FederationСанкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова, Санкт-ПетербургРоссияPavlov St Petersburg State Medical University, St PetersburgRussian Federation201328062013193212220Copyright © Маслянский А.Л., Колесова Е.П., Пенин И.Н., Чешуина М.Д., Лапин С.В., Конради А.О., 20132013Маслянский А.Л., Колесова Е.П., Пенин И.Н., Чешуина М.Д., Лапин С.В., Конради А.О.Maslyanskiy A.L., Kolesovа E.P., Penin I.N., Cheshuina M.D., Lapin S.V., Konradi A.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/139Актуальность

Актуальность. Жесткость артериальной сосудистой стенки является независимым предиктором кардиоваскулярной смерти среди различных популяций пациентов. В настоящее время проведено несколько исследований, результаты которых свидетельствуют о повышении жесткости артериальной стенки при системной склеродермии (ССД). Влияние иммуносупрессивной терапии на жесткость сосудистой стенки у больных ССД не исследовано.

Материалы и методы

Материалы и методы. Авторами данной статьи выполнена оценка сосудистой жесткости 5 больным диффузной формой склеродермии до и через 6 месяцев после сочетанной иммуносупрессивной терапии.

Выводы

Выводы. У всех больных наблюдалось снижение показателей сосудистой жесткости на фоне умеренного эффекта от проводимой терапии.

Background

Background. Arterial wall stiffness is an independent predictor of cardiovascular mortality in different patient populations. Currently, there are several studies that show an increase of arterial wall stiffness in systemic sclerosis (SSc). The effect of immunosuppressive therapy on vascular wall stiffness in SSc patients is not investigated. The authors of this paper attempted to study the effect of rituximab and cyclophosphamide combination therapy on vascular stiffness in 5 patients with diffuse form of SSc.

Design and methods

Design and methods. We assessed arterial stiffness in 5 patients with diffuse form of SSc before and after 6 months after combined immunosuppressive therapy.

Conclusion

Conclusion. The parameters of arterial stiffness decreased in all patients with the moderate effect of the therapy.

системная склеродермияжесткость сосудистой стенкианти В-клеточная терапияритуксимаб.systemic sclerodermaarterial wall stiffnessanti-B cell therapyrituximabReferencesKatsumoto T.R., Whitfield M.L., Connolly M.K. The pathogenesis of systemic sclerosis // Annu Rev. Pathol. — 2011. — Vol. 6. — P. 509–537.Katsumoto T.R., Whitfield M.L., Connolly M.K. The pathogenesis of systemic sclerosis // Annu Rev. Pathol. — 2011. — Vol. 6. — P. 509–537.Herrick A.L. Vascular function in systemic sclerosis // Curr. Opin. Rheumatol. — 2000. — Vol. 12, № 6. — P. 527–533.Herrick A.L. Vascular function in systemic sclerosis // Curr. Opin. Rheumatol. — 2000. — Vol. 12, № 6. — P. 527–533.Weissberg P.L. Atherogenesis: current understanding of the causes of atheroma // Heart. — 2000. — Vol. 83, № 2. — P. 247–252.Weissberg P.L. Atherogenesis: current understanding of the causes of atheroma // Heart. — 2000. — Vol. 83, № 2. — P. 247–252.Пенин И.Н., Колесова Е.П., Маслянский А.Л., Чешуина М.Д., Конради А.О. Структура кардиоваскулярной патологии и механизмы ее развития у больных системной склеродермией // Бюлл. Федерального Центра сердца, крови и эндокринологии им. В.А. Алмазова. — 2012. — № 2. — С. 76–81. / Penin I.N., Kolesova E.P., Maslyanskiy A.L., Cheshuina M.D., Konradi A.O. The structure and pathogenesis of cardiovascular diseases in patients with systemic sclerosis // Bulletin of Almazov Federal Heart, Blood and Endocrinology Centre [Bulleten Federalnogo Tsentra Serdtsa, Krovi i Endocrinologii imeni V.A. Almazova]. — 2012. — № 2. — P. 76–81 [Russian].Пенин И.Н., Колесова Е.П., Маслянский А.Л., Чешуина М.Д., Конради А.О. Структура кардиоваскулярной патологии и механизмы ее развития у больных системной склеродермией // Бюлл. Федерального Центра сердца, крови и эндокринологии им. В.А. Алмазова. — 2012. — № 2. — С. 76–81. / Penin I.N., Kolesova E.P., Maslyanskiy A.L., Cheshuina M.D., Konradi A.O. The structure and pathogenesis of cardiovascular diseases in patients with systemic sclerosis // Bulletin of Almazov Federal Heart, Blood and Endocrinology Centre [Bulleten Federalnogo Tsentra Serdtsa, Krovi i Endocrinologii imeni V.A. Almazova]. — 2012. — № 2. — P. 76–81 [Russian].Pattanaik D., Brown M., Postlethwaite A.E. Vascular involvement in systemic sclerosis (scleroderma) // J. Infl amm. Res. — 2011. — Vol. 4. — P. 105–125.Pattanaik D., Brown M., Postlethwaite A.E. Vascular involvement in systemic sclerosis (scleroderma) // J. Infl amm. Res. — 2011. — Vol. 4. — P. 105–125.Wilkinson I.B., Fuchs S.A., Jansen I.M. et al. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis // J. Hypertens. — 1998. — Vol. 16, № 12, Pt. 2. — P. 2079–2084.Wilkinson I.B., Fuchs S.A., Jansen I.M. et al. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis // J. Hypertens. — 1998. — Vol. 16, № 12, Pt. 2. — P. 2079–2084.Laurent S., Cockcroft J., Van Bortel L. et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications // Eur. Heart J. — 2006. — Vol. 27, № 21. — P. 2588–2605.Laurent S., Cockcroft J., Van Bortel L. et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications // Eur. Heart J. — 2006. — Vol. 27, № 21. — P. 2588–2605.Cheng K.S., Tiwari A., Boutin A. et al. Carotid and femoral arterial wall mechanics in scleroderma // Rheumatology (Oxford). — 2003. — Vol. 42, № 11. — P. 1299–1305.Cheng K.S., Tiwari A., Boutin A. et al. Carotid and femoral arterial wall mechanics in scleroderma // Rheumatology (Oxford). — 2003. — Vol. 42, № 11. — P. 1299–1305.Cypiene A., Laucevicius A., Venalis A. et al. Non-invasive assessment of arterial stiffness indices by applanation tonometry and pulse wave analysis in patients with rheumatoid arthritis treated with TNF-alpha blocker remicade (infl iximab) // Proc. West Pharmacol. Soc. — 2007. — Vol. 50. — P. 119–122.Cypiene A., Laucevicius A., Venalis A. et al. Non-invasive assessment of arterial stiffness indices by applanation tonometry and pulse wave analysis in patients with rheumatoid arthritis treated with TNF-alpha blocker remicade (infl iximab) // Proc. West Pharmacol. Soc. — 2007. — Vol. 50. — P. 119–122.Timar O., Soltesz P., Szamosi S. et al. Increased arterial stiffness as the marker of vascular involvement in systemic sclerosis // J. Rheumatol. — 2008. — Vol. 35, № 7. — P. 1329–1333.Timar O., Soltesz P., Szamosi S. et al. Increased arterial stiffness as the marker of vascular involvement in systemic sclerosis // J. Rheumatol. — 2008. — Vol. 35, № 7. — P. 1329–1333.Au K., Khanna D., Clements P.J. et al. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials // Curr. Rheumatol. Rep. — 2009. — Vol. 11, № 2. — P. 111–119.Au K., Khanna D., Clements P.J. et al. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials // Curr. Rheumatol. Rep. — 2009. — Vol. 11, № 2. — P. 111–119.Bosello S., De Santis M., Lama G. et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modifi cation and IL-6 modulation in an up to thirty-six months follow-up open-label trial // Arthritis Res. Ther. — 2010. — Vol. 12, № 2. — P. R54.Bosello S., De Santis M., Lama G. et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modifi cation and IL-6 modulation in an up to thirty-six months follow-up open-label trial // Arthritis Res. Ther. — 2010. — Vol. 12, № 2. — P. R54.Smith V., Van Praet J.T., Vandooren B. et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study // Ann. Rheum. Dis. — 2010. — Vol. 69, № 1. — P. 193–197.Smith V., Van Praet J.T., Vandooren B. et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study // Ann. Rheum. Dis. — 2010. — Vol. 69, № 1. — P. 193–197.Edwards J.C., Szczepanski L., Szechinski J. et al. Effi cacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis // N. Engl. J. Med. — 2004. — Vol. 350, № 25. — P. 2572–2581.Edwards J.C., Szczepanski L., Szechinski J. et al. Effi cacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis // N. Engl. J. Med. — 2004. — Vol. 350, № 25. — P. 2572–2581.Lu T.Y., Ng K.P., Cambridge G. et al. A retrospective sevenyear analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the fi rst fi fty patients // Arthritis Rheum. — 2009. — Vol. 61, № 4. — P. 482–487.Lu T.Y., Ng K.P., Cambridge G. et al. A retrospective sevenyear analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the fi rst fi fty patients // Arthritis Rheum. — 2009. — Vol. 61, № 4. — P. 482–487.Mitchell G.F., Hwang S.J., Vasan R.S. et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study // Circulation. — 2010. — Vol. 121, № 4. — P. 505–511.Mitchell G.F., Hwang S.J., Vasan R.S. et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study // Circulation. — 2010. — Vol. 121, № 4. — P. 505–511.Cecelja M., Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review // Hypertension. — 2009. — Vol. 54, № 6. — P. 1328–1336.Cecelja M., Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review // Hypertension. — 2009. — Vol. 54, № 6. — P. 1328–1336.Bodnar N., Kerekes G., Seres I. et al. Assessment of subclinical vascular disease associated with ankylosing spondylitis // J. Rheumatol. — 2011. — Vol. 38, № 4. — P. 723–729.Bodnar N., Kerekes G., Seres I. et al. Assessment of subclinical vascular disease associated with ankylosing spondylitis // J. Rheumatol. — 2011. — Vol. 38, № 4. — P. 723–729.Soltesz P., Der H., Kerekes G. et al. A comparative study of arterial stiffness, fl ow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases // Clin. Rheumatol. — 2009. — Vol. 28, № 6. — P. 655–662.Soltesz P., Der H., Kerekes G. et al. A comparative study of arterial stiffness, fl ow-mediated vasodilation of the brachial artery, and the thickness of the carotid artery intima-media in patients with systemic autoimmune diseases // Clin. Rheumatol. — 2009. — Vol. 28, № 6. — P. 655–662.Soltesz P., Kerekes G., Der H. et al. Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment // Autoimmun. Rev. — 2011. — Vol. 10, № 7. — P. 416–425.Soltesz P., Kerekes G., Der H. et al. Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment // Autoimmun. Rev. — 2011. — Vol. 10, № 7. — P. 416–425.Zardi E.M., Afeltra A. Endothelial dysfunction and vascular stiffness in systemic lupus erythematosus: а re they early markers of subclinical atherosclerosis? // Autoimmun. Rev. — 2010. — Vol. 9, № 10. — P. 684–686.Zardi E.M., Afeltra A. Endothelial dysfunction and vascular stiffness in systemic lupus erythematosus: а re they early markers of subclinical atherosclerosis? // Autoimmun. Rev. — 2010. — Vol. 9, № 10. — P. 684–686.Provan S.A., Angel K., Semb A.G. et al. Early prediction of increased arterial stiffness in patients with chronic infl ammation: a 15-year followup study of 108 patients with rheumatoid arthritis // J. Rheumatol. — 2011. — Vol. 38, № 4. — P. 606–612.Provan S.A., Angel K., Semb A.G. et al. Early prediction of increased arterial stiffness in patients with chronic infl ammation: a 15-year followup study of 108 patients with rheumatoid arthritis // J. Rheumatol. — 2011. — Vol. 38, № 4. — P. 606–612.Shang Q., Tam L.S., Li E.K. et al. Increased arterial stiffness correlated with disease activity in systemic lupus erythematosus // Lupus. — 2008. — Vol. 17, № 12. — P. 1096–1102.Shang Q., Tam L.S., Li E.K. et al. Increased arterial stiffness correlated with disease activity in systemic lupus erythematosus // Lupus. — 2008. — Vol. 17, № 12. — P. 1096–1102.Constans J., Germain C., Gosse P. et al. Arterial stiffness predicts severe progression in systemic sclerosis: the ERAMS study // J. Hypertens. — 2007. — Vol. 25, № 9. — P. 1900–1906.Constans J., Germain C., Gosse P. et al. Arterial stiffness predicts severe progression in systemic sclerosis: the ERAMS study // J. Hypertens. — 2007. — Vol. 25, № 9. — P. 1900–1906.Andersen G.N., Mincheva-Nilsson L., Kazzam E. et al. Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production // Arthritis Rheum. — 2002. — Vol. 46, № 5. — P. 1324–1332.Andersen G.N., Mincheva-Nilsson L., Kazzam E. et al. Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production // Arthritis Rheum. — 2002. — Vol. 46, № 5. — P. 1324–1332.Van Doornum S., McColl G., Wicks I.P. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis // Ann. Rheum. Dis. — 2004. — Vol. 63, № 12. — P. 1571–1575.Van Doornum S., McColl G., Wicks I.P. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis // Ann. Rheum. Dis. — 2004. — Vol. 63, № 12. — P. 1571–1575.Angel K., Provan S.A., Gulseth H.L. et al. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with infl ammatory arthropathies: a controlled study // Hypertension. — 2010. — Vol. 55, № 2. — P. 333–338.Angel K., Provan S.A., Gulseth H.L. et al. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with infl ammatory arthropathies: a controlled study // Hypertension. — 2010. — Vol. 55, № 2. — P. 333–338.Angel K., Provan S.A., Hammer H.B. et al. Changes in arterial stiffness during continued infl iximab treatment in patients with infl ammatory arthropathies // Fundam. Clin. Pharmacol. — 2011. — Vol. 25, № 4. — P. 511–517.Angel K., Provan S.A., Hammer H.B. et al. Changes in arterial stiffness during continued infl iximab treatment in patients with infl ammatory arthropathies // Fundam. Clin. Pharmacol. — 2011. — Vol. 25, № 4. — P. 511–517.Kerekes G., Soltesz P., Der H. et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profi le in rheumatoid arthritis // Clin. Rheumatol. — 2009. — Vol. 28, № 6. — P. 705–710.Kerekes G., Soltesz P., Der H. et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profi le in rheumatoid arthritis // Clin. Rheumatol. — 2009. — Vol. 28, № 6. — P. 705–710.Mathieu S., Pereira B., Dubost J.J. et al. No signifi cant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment // Rheumatology (Oxford). — 2012. — Vol. 51, № 6. — P. 1107–1111.Mathieu S., Pereira B., Dubost J.J. et al. No signifi cant change in arterial stiffness in RA after 6 months and 1 year of rituximab treatment // Rheumatology (Oxford). — 2012. — Vol. 51, № 6. — P. 1107–1111.

The authors declare that there are no conflicts of interest present.